23andMe Holding Co Class A ME
Find similar stocks with Morningstar Investor.
Morningstar analysts do not currently cover ME, but with our powerful screener, you can find stocks in the same sector, industry, or style and filter on our unbiased ratings and valuation metrics.
News
-
23andMe to Present Preliminary Efficacy and Biomarker Data for 23ME-00610 at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
-
23andMe announces CEO’s intention to pursue a potential take-private
-
CEO Anne Wojcicki looking to take 23andMe private
-
23andMe to Present Data on Two Clinical Stage Immuno-Oncology Programs at the American Association for Cancer Research (AACR) Annual Meeting 2024
-
23andMe Initiates Phase 1 Clinical Trial for its Dual Mechanism Antibody, 23ME-01473, Targeting ULBP6
-
23andMe Launches New Feature Connecting Customers to Historical Individuals from Hundreds and Even Thousands of Years Ago
-
23andMe Launches New Genetic Reports on Common Forms of Cancer
-
23andMe Announces Three Presentations from Clinical-Stage Immuno-Oncology Programs at the American Association for Cancer Research (AACR) Annual Meeting 2024
Trading Information
- Previous Close Price
- $0.46
- Day Range
- $0.45–0.48
- 52-Week Range
- $0.35–2.21
- Bid/Ask
- $0.46 / $0.47
- Market Cap
- $224.12 Mil
- Volume/Avg
- 2.6 Mil / 7.8 Mil
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 0.87
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
23andMe Holding Co is a consumer-facing healthcare technology company, primarily involved in the sale of direct-to-consumer personal genome services, or PGS, through DNA collection kits shipped via mail. The company provides users access to reports summarizing estimated genetic ancestry breakdown, phenotypic trait reports, and various health predisposition and disease carrier reports. Its segment include Consumer and Research Services and Therapeutics. The company generates maximum revenue from the Consumer and Research Services segment.
- Sector
- Healthcare
- Industry
- Diagnostics & Research
- Stock Style Box
- Small Value
- Total Number of Employees
- 816
- Website
- https://www.23andme.com
Comparables
Valuation
|
Metric
|
ME
|
IQV
|
MYGN
|
|---|---|---|---|
Price/Earnings (Normalized) | — | 23.59 | — |
Price/Book Value | 0.59 | 7.15 | 2.06 |
Price/Sales | 0.87 | 2.99 | 1.98 |
Price/Cash Flow | — | 18.47 | — |
Price/Earnings
ME
IQV
MYGN
Financial Strength
|
Metric
|
ME
|
IQV
|
MYGN
|
|---|---|---|---|
Quick Ratio | 1.85 | 0.76 | 1.64 |
Current Ratio | 2.15 | 0.86 | 2.01 |
Interest Coverage | — | 3.12 | −90.28 |
Quick Ratio
ME
IQV
MYGN
Profitability
|
Metric
|
ME
|
IQV
|
MYGN
|
|---|---|---|---|
Return on Assets (Normalized) | −22.54% | 7.32% | −1.93% |
Return on Equity (Normalized) | −30.47% | 32.37% | −2.88% |
Return on Invested Capital (Normalized) | −29.17% | 12.78% | −2.33% |
Return on Assets
ME
IQV
MYGN
Diagnostics & Research Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
TMO
| Thermo Fisher Scientific Inc | Qlykllyzr | Jbcn | $209.3 Bil | |
DHR
| Danaher Corp | Wkgstnvvn | Ryyfg | $182.1 Bil | |
IQV
| IQVIA Holdings Inc | Fvtygwvd | Nxjnxtv | $43.4 Bil | |
IDXX
| IDEXX Laboratories Inc | Rnvxlpwt | Qcrtrp | $41.0 Bil | |
A
| Agilent Technologies Inc | Htgbnhjz | Blcnj | $40.3 Bil | |
MTD
| Mettler-Toledo International Inc | Jqmtcvcpy | Gyvjx | $26.4 Bil | |
ICLR
| Icon PLC | Dklgrlgb | Xprnspn | $24.8 Bil | |
ILMN
| Illumina Inc | Zjrdwrqm | Yysyyf | $19.3 Bil | |
WAT
| Waters Corp | Lmyrdlqkp | Phyjf | $18.3 Bil | |
LH
| Laboratory Corp of America Holdings | Jgycthbqy | Ykzdj | $17.5 Bil |